Scholarlink

<p>We analyzed the impact of the diagnosis-to-treatment interval (DTI) on survival in patients with CD5-positive diffuse large B-cell lymphoma (CD5 + DLBCL), using a data set of newly diagnosed patients. Among the 336 eligible patients, 247 (74%) received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone), and 89 (26%) were treated with dose-adjusted (DA)-EPOCH-R (etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and rituximab). The median DTI was 18&#xa0;days (range 0–118). The short DTI (≤ 14&#xa0;days) group included 135 patients (40%), and the long DTI (&gt; 14&#xa0;days) group included 201 patients (60%). Compared with the long DTI group, the short DTI group had more aggressive disease characteristics. Both the progression-free survival (PFS) (<i>P</i> = 0.01) and the overall survival (OS) (<i>P</i> &lt; 0.01) were significantly inferior in the short DTI group compared with those in the long DTI group. Among 89 patients who received DA-EPOCH-R, no significant differences in PFS (<i>P</i> = 0.92) or OS (<i>P</i> = 0.86) were observed between the two groups. Multivariate analysis revealed that no DA-EPOCH-R was a risk factor for PFS in the short DTI group (<i>P</i> = 0.06). A short DTI was a negative prognostic factor in our CD5 + DLBCL cohort. DA-EPOCH-R could be considered a potential treatment option for patients with a short DTI.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of the diagnosis-to-treatment interval on the survival of patients with CD5-positive diffuse large B-cell lymphoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月25日

查看全文
  • Yuma Nato,
  • Kana Miyazaki,
  • Dai Maruyama,
  • Hiroyuki Takahashi,
  • Kazutaka Sunami,
  • Eiju Negoro,
  • Satsuki Murakami,
  • Takahiro Okada,
  • Nobuyuki Takayama,
  • Yuri Miyazawa,
  • Ilseung Choi,
  • Shuji Momose,
  • Yuto Kaneda,
  • Masahiro Yoshida,
  • Naoto Tomita,
  • Tohru Murayama,
  • Momoko Nishikori,
  • Junji Hiraga,
  • Kohtaro Toyama,
  • Naoki Takahashi,
  • Taro Masunari,
  • Jun Takizawa,
  • Isao Tawara,
  • Naoko Asano,
  • Koichi Ohshima,
  • Koji Izutsu,
  • Koji Kato,
  • Ritsuro Suzuki,
  • Motoko Yamaguchi

摘要

We analyzed the impact of the diagnosis-to-treatment interval (DTI) on survival in patients with CD5-positive diffuse large B-cell lymphoma (CD5 + DLBCL), using a data set of newly diagnosed patients. Among the 336 eligible patients, 247 (74%) received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone), and 89 (26%) were treated with dose-adjusted (DA)-EPOCH-R (etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, and rituximab). The median DTI was 18 days (range 0–118). The short DTI (≤ 14 days) group included 135 patients (40%), and the long DTI (> 14 days) group included 201 patients (60%). Compared with the long DTI group, the short DTI group had more aggressive disease characteristics. Both the progression-free survival (PFS) (P = 0.01) and the overall survival (OS) (P < 0.01) were significantly inferior in the short DTI group compared with those in the long DTI group. Among 89 patients who received DA-EPOCH-R, no significant differences in PFS (P = 0.92) or OS (P = 0.86) were observed between the two groups. Multivariate analysis revealed that no DA-EPOCH-R was a risk factor for PFS in the short DTI group (P = 0.06). A short DTI was a negative prognostic factor in our CD5 + DLBCL cohort. DA-EPOCH-R could be considered a potential treatment option for patients with a short DTI.